Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: TinfoilHat who wrote (53439)	12/14/2019 12:43:13 PM
From: trickydick	Respond to of 63291

TinHat This is an exceptional summary of where we are right now and the places we may go to. The market need is amazing, the good it can do, the lives to save, the bank accounts to be enlarged, etc... Okay, the last part wasn't necessary, but, it's the truth. Do you think FDA sees an analysis or outline of the potential of a submitted product? I'm sure they do, but to what effect is this information? I doubt they monitor this or any other general public forum. Is it possible for any of us to make such an effort to inform them of one part of science that can and should be advanced as rapidly as possible? Does anyone have any type of contact information for the FDA he/she could share with us? If so, perhaps we can send some individual, heart felt opinions of the benefits of the approval of 132. It seems like we have an opportunity, and perhaps, even an obligation to send opinions and comments to the FDA in the hopes it could save even one life, it's worth the effort.

To: TinfoilHat who wrote (53439)	12/14/2019 1:54:13 PM
From: idahoranch1	1 Recommendation Recommended By erippetoe Read Replies (1) \| Respond to of 63291

I tip my hat to you Tin, that was information laid out in a way any of us can understand. We’ve had it in bits and pieces, but not all at one time and in a way we can remember it all, or go back to. I also put it in a file. Silly is still very much in the cards. It just doesn’t happen overnight and there’s generally a little luck involved, like “The treatment works well in several indications”.

To: TinfoilHat who wrote (53439)	12/14/2019 2:56:31 PM
From: Renmanco	14 Recommendations Recommended By bnutman bobbseytwins2001 dorightbythem EMU2 idahoranch1 and 9 more members Respond to of 63291

Tin: What a masterful summary of where we might actually be in the relatively near future....outstanding. One small (very small) nit is that 85% of 42K patients is 35,700. Another personal reminder. I keep on my computer an automated birthday reminder and today I was reminded that today was the birthday of my daughter who would have been 44 had she not passed from pancreatic cancer in 2014. (She was also burdened with cerebral palsy her entire life and was tube-fed, non-verbal and bed-ridden since about eight years of age). Free of those earthly afflictions, I hope she is playing and having fun in heaven....and knows that there are many people here who are working hard to eradicated this damn disease from the face of the earth. This is why I invest here and support St. Jude Children's Research Hospital.

To: TinfoilHat who wrote (53439)	12/14/2019 8:56:51 PM
From: JohnBeach	9 Recommendations Recommended By bnutman corndog CPark erippetoe idahoranch1 and 4 more members Read Replies (2) \| Respond to of 63291

Tin. DS8201 is the Daiichi HER2- targeting ADC that was presented at SABCS. It doesn't target trop2; it was never perceived as a competitor to SG in TNBC, NSCLC or any other target. DS1602 is the Daiichi TROP2 ADC that was perceived to be a threat to SG. It's in phase I in NSCLC and because it targets Trop2 the concern was that it could be first mover in LC and move into the TNBC space as well. IMMU shares had been under a DS1602 cloud for months, but spiked Sept 10 when the updated data on 1602 revealed a safety signal related to ILD. They are different compounds, but with the same ILD problem. It suggests that the is an issue with the ADC construct.